Lundbeck works with healthcare professionals when developing and delivering new treatment options to people living with psychiatric and neurological diseases. We believe this collaborative working benefits patients and society.
Lundbeck is an innovative, global pharmaceutical company that works with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) when developing and delivering new treatment options to people living with psychiatric and neurological diseases.
Our interactions with HCPs and HCOs are well-regulated by legal requirements, codes of practices from industry associations we have joined and Lundbeck’s internal procedures, legal and ethical standards. The interactions include research activities, clinical development of new treatments, exchanges of scientific information, marketing and sales activities.
Lundbeck is committed to promoting transparency by disclosing payments and other transfers of value to HCPs and HCOs according to our global procedures that respect current laws and self-regulation from the industry associations we have joined e.g. the EFPIA Disclosure Code.
Under this Code, the EFPIA member companies will disclose the names of HCPs and HCOs that have received payments or other transfers of value from them. The data is disclosed by HCP or HCO and includes the total annual amounts of value transferred, by type of activity e.g. a grant to an HCO, a consultancy fee for speaking, payment for travel or registration fees to attend a medical education congress.
The first disclosures are made on 30 June 2016 for payments made in 2015.
How have the data been calculated?
Curious to learn more about how the numbers have been calculated, how we've organised the data and which countries are in scope? Below Methodological Note describes more about the numbers that you find here on this website as well as the specific countries we show here.